SEC Form 4 · Rule 10b5-1 trading plans

Akero Therapeutics, Inc. (AKRO)

58Trades filed under a plan
0Plan adoption dates stated
4Quarterly results prints on file
15Trades in the days before a print

In the 2025 filing year, Akero Therapeutics, Inc. filed 25 Form 4 statements whose footnotes name a Rule 10b5-1 trading plan, by 5 reporting owners, covering 58 transactions filed under those plans and 517,460 shares. 25 of those filings carry the SEC's own AFF10B5ONE adoption flag; the other 0 name a plan in a footnote and carry no flag. 4 results prints are on file in the same window, which is what makes the interval below measurable.

Trades filed under a plan in Akero Therapeutics, Inc. 58

Plan adoption dates stated in Akero Therapeutics, Inc. 0

Quarterly results prints on file in Akero Therapeutics, Inc. 4

Trades in the days before a print in Akero Therapeutics, Inc. 15

Interval to the next reported results date

For each transaction filed under a plan, the days between the transaction date and the company’s next results print. These are the dates the filings state, printed as an interval; the page draws no conclusion from them.

15Within 5 days of a print
17Within 10 days of a print
0Shortest interval, in days
14Trades with no later print on file

Reported results dates on file

A proxy statement is on file for this company in the same window, which is where a company states its own trading policy.

Other companies with plan records

Order the document

Every company with plan records →

Form 4 statements and their footnotes from the SEC’s EDGAR full-text search, and this company’s results dates, industry classification and state of incorporation from the SEC submissions API. The page prints the dates the filings state and the interval between them; it draws no conclusion from them.